Skip to main content

ORIGINAL RESEARCH article

Front. Cell Dev. Biol.
Sec. Cancer Cell Biology
Volume 12 - 2024 | doi: 10.3389/fcell.2024.1448037

Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer

Provisionally accepted
Yuanyuan Shen Yuanyuan Shen 1Qingling Hua Qingling Hua 1Menghao Dong Menghao Dong 2Wei Jin Wei Jin 2Yanzhe Zhu Yanzhe Zhu 1Kangsheng Gu Kangsheng Gu 1*
  • 1 First Affiliated Hospital of Anhui Medical University, Hefei, China
  • 2 University of Science and Technology of China, Hefei, Anhui Province, China

The final, formatted version of the article will be published soon.

    Aim: This study aims to compare the efficiencies and toxicities of pegylated liposomal doxorubicin (PLD) based and epirubicin based chemotherapeutic regimens as neoadjuvant chemotherapy (NAC) for early breast cancer.We retrospectively analyzed 391 patients with stage II-III breast cancer who received NAC in multiple centers. The efficiencies and toxicities of PLD and epirubicin based NAC regimens were compared by using both propensityscore matched (PSM) and unmatched data. The status of relevant gene loci was detected through next generation sequencing (NGS) technology and the correlation between mutations of genes and serious adverse events (AEs) was preliminarily analyzed.Results: A total of 391 patients were included in this study. Among them, 235 patients received PLD based NAC (PLD group), and the other 156 patients were administrated with EPI based NAC (EPI group). The pathological complete response (pCR) rate of patients in PLD group was significantly higher than EPI group (before PSM:32.3% vs. 23.1%; after PSM:42.5% vs. 24.7%). Most severe AEs of patients in EPI group were more than PLD group (before PSM: 1.3%-37.8% vs. 0-10.6%; after PSM: 1.4%-37.0% vs. 0-9.6%). Mutation rates of 7 gene (MTHFR, DPYD, NQO1, ERCC1, UGT1A1, TYMS and TP53) of patients with severe AEs were significantly higher compared with patients with slight AEs (grade 1/2) or without AEs.Conclusions： PLD based chemotherapeutic regimen is a viable option for NAC of breast cancer. Epirubicin should be avoided for patients with mutations of some specific genes considering the potential severe AEs.

    Keywords: breast cancer, Neoadjuvant chemotherapy, Pegylated liposomal doxorubicin, Epirubicin, efficacy

    Received: 13 Jun 2024; Accepted: 06 Dec 2024.

    Copyright: © 2024 Shen, Hua, Dong, Jin, Zhu and Gu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Kangsheng Gu, First Affiliated Hospital of Anhui Medical University, Hefei, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.